Candidiasis - Pipeline Insight, 2024

Candidiasis - Pipeline Insight, 2024

DelveInsight’s, “Candidiasis - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Candidiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Candidiasis Understanding

Candidiasis: Overview

Candidiasis is an infection caused by a fungus called Candida; most commonly the Candida albicans variety. The Candida infection (also known as a yeast infection) usually affects the skin and/or the mucous membranes of the mouth, intestines, or the vagina. Candida infections are rarely serious in otherwise healthy people. In rare cases, it may spread through other parts of the body if the patient’s immune system is not functioning properly. In the most severe cases it can affect the blood, the membrane lining the heart muscle (endocardium), or membranes around the brain (meninges). Candidiasis is caused by a normally harmless infection with the yeast fungus of the genus Candida, usually Candida albicans (Monilia albicans). The yeast is supposed to be present in healthy people. However, the fungus may multiply in the mouth or the bowels when a patient receives chemotherapy or broad spectrum antibiotics which suppress the bacterial flora which are normally present in the body. Other health conditions such as pregnancy or diabetes mellitus may also make the patient prone to a Candida infection. A very wide range of symptoms can be caused by the Candida infection, from the mildest and more common forms that usually affect the mouth and vagina, to the most rare and severe forms which may affect the heart or brain.

""Candidiasis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Candidiasis pipeline landscape is provided which includes the disease overview and Candidiasis treatment guidelines. The assessment part of the report embraces, in depth Candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Angelman Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Candidiasis.

Candidiasis Emerging Drugs Chapters

This segment of the Candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Candidiasis Emerging Drugs

• Rezafungin: Cidara Therapeutics

Rezafungin is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections. Rezafungin’s structure and properties have been precisely refined to retain the safety benefits of echinocandin drugs while enhancing its pharmacokinetic and pharmacodynamic properties to create a longer-lasting, next-generation treatment and preventative, capable of addressing even drug-resistant species. To date, data demonstrate that rezafungin has potent antifungal activity against representative strains of Candida spp., Aspergillus spp., Pneumocystis spp. and dermatophytes. In addition, rezafungin has potent activity against fungal pathogens designated as Urgent and Serious Threats by the CDC. In January 2023, Cidara Therapeutics and Melinta Therapeutics, announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 22, 2023, enabled by rezafungin’s designation as a Qualified Infectious Disease Product (QIDP).

• MAT2203: MATINAS BIOPHARMA HOLDINGS

Leveraging the LNC technology, the company has developed MAT2203 – an oral and non-toxic encochleated form of amphotericin B (CAmB). This antifungal drug is the primary broad-spectrum treatment for immunocompromised patients. Unlike some other therapies, it doesn’t simply stop fungus from growing, but kills it entirely. Until now, amphotericin B has only been available through intravenous administration, which can lead to kidney or “renal” toxicity. Combining the same level of fungicidal efficacy with targeted delivery and a lower risk of toxicity, MAT2203 has the potential to be a game changer. It delivers CAmB directly to the infected tissues, shielding the body from unnecessary exposure to the drug. Patients who take it could also benefit from shorter hospital stays, lower costs and easier access to amphotericin B.

Further product details are provided in the report……..

Candidiasis: Therapeutic Assessment

This segment of the report provides insights about the different Candidiasis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Candidiasis

There are approx. 15+ key companies which are developing the therapies for Candidiasis. The companies which have their Candidiasis drug candidates in the most advanced stage, i.e. Registered include, Cidara Therapeutics.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Candidiasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Candidiasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Candidiasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Candidiasis drugs.

Candidiasis Report Insights

• Candidiasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Candidiasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Candidiasis drugs?
• How many Candidiasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Candidiasis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Candidiasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Candidiasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cidara Therapeutics
• MATINAS BIOPHARMA HOLDINGS
• ProFem GmbH
• CelaCare Technologies, Inc.
• SCYNEXIS
• NovaDigm Therapeutics
• NovaBiotics Ltd
• Stadius Biopharma
• Mycovia Pharmaceuticals
• ORYN THERAPEUTICS
• Biocidium Biopharmaceuticals
• Hyloris Pharmaceuticals

Key Products

• Rezafungin
• MAT2203
• Prof-001
• CelAgace
• SCY 078
• NDV 3
• NP339
• MSC Candida
• VT-1598
• BCM-0882
• BCM-0915
• MCZ-DB